INDIVIOR PLC/S (OTCMKTS:INVVY) was downgraded by Zacks Investment Research from a “hold” rating to a “strong sell” rating in a research report issued on Friday, reports.

According to Zacks, “Indivior PLC operates as a specialty pharmaceutical company. It is engaged in discovering and developing medications and treatment for alcohol addiction, opioid overdose, cocaine intoxication and co-occurring conditions, such as schizophrenia. The Company markets and promotes SUBOXONE (buprenorphine and naloxone) Sublingual Film, SUBOXONE (buprenorphine and naloxone) Sublingual Tablet, and SUBUTEX (buprenorphine) Sublingual Tablet, each buprenorphine-based treatment for opioid. Indivior PLC is based in United States. “

INVVY traded up $0.01 during trading on Friday, hitting $2.43. 10,027 shares of the stock traded hands, compared to its average volume of 18,826. The firm has a market capitalization of $358.54 million, a P/E ratio of 2.86 and a beta of -0.20. The firm has a 50-day moving average of $2.59 and a 200 day moving average of $2.92. INDIVIOR PLC/S has a 12-month low of $1.98 and a 12-month high of $7.74.

INDIVIOR PLC/S (OTCMKTS:INVVY) last announced its quarterly earnings results on Thursday, February 13th. The company reported ($0.25) earnings per share for the quarter. The firm had revenue of $133.00 million for the quarter. INDIVIOR PLC/S had a net margin of 17.07% and a return on equity of 132.33%. As a group, equities research analysts expect that INDIVIOR PLC/S will post 0.11 EPS for the current fiscal year.


Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The company's product pipeline focuses on treating opioid use disorder, alcohol use disorder, opiate overdose, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex.

Recommended Story: Liquidity

Get a free copy of the Zacks research report on INDIVIOR PLC/S (INVVY)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for INDIVIOR PLC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INDIVIOR PLC/S and related companies with's FREE daily email newsletter.